The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A randomized pilot study comparing safety and efficacy of irinotecan plus S-1 (IRIS) plus bevacizumab (BV) and modified (m) FOLFIRI plus BV in patients (pts) with metastatic colorectal cancer (mCRC): First report of T-CORE0702.
Shunsuke Kato
Disclosure not yet available
Hideaki Andoh
Disclosure not yet available
Makio Gamoh
Disclosure not yet available
Takuhiro Yamaguchi
Disclosure not yet available
Yasuko Murakawa
Disclosure not yet available
Yuka Sasaki
Disclosure not yet available
Shin Takahashi
Disclosure not yet available
Hideki Shimodaira
Disclosure not yet available
Takashi Yoshioka
Disclosure not yet available
Chikashi Ishioka
Disclosure not yet available